Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Gadobenate Dimeglumine→

Gadobenate Dimeglumine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
127000-20-8
Molecular formula
C36H62GdN5O21
Molecular weight
1058.1 g/mol
Drug class
Gadolinium-based paramagnetic magnetic-resonance imaging (MRI) contrast agent
Mechanism of action
A gadolinium chelate that develops a magnetic moment in a magnetic field and shortens the T1 and, to a lesser extent, T2 relaxation times of nearby water protons, increasing MRI signal intensity.
Indications / reported uses
  • Contrast enhancement in MRI of the central nervous system and selected liver imaging applications, according to the product label and jurisdiction.

Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/gadobenate-dimeglumine · https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f63abe56-46d9-4e32-afb1-f4e22370717d

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Gadobenate Dimeglumine Environmental Risk Assessment (ERA) (the Gadobenate Dimeglumine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.